This site may require a log-in in the near future. We are constantly being swamped by AI agents. If they continue to take down the site, we will be changing to requiring logins to access any item.

🍽️ nilutamide,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Prostate Cancer: Nilutamide is classified as an antiandrogen medication and is used in combination with other treatments (such as surgical castration or luteinizing hormone-releasing hormone agonists) for the treatment of metastatic prostate cancer in men. It works by blocking the effects of androgens (male hormones) on the prostate cancer cells, thereby slowing down the growth and spread of the cancer.

  2. Androgen Blockade: Nilutamide competitively inhibits the binding of androgens (such as testosterone) to androgen receptors in prostate cancer cells. By blocking the androgen receptors, nilutamide interferes with the signaling pathways that promote the growth and survival of prostate cancer cells. This antiandrogenic effect helps to suppress the progression of prostate cancer and may lead to a reduction in tumor size and serum prostate-specific antigen (PSA) levels.

  3. Metastatic Disease: Nilutamide is particularly beneficial in the treatment of metastatic prostate cancer, where the cancer has spread beyond the prostate gland to other parts of the body, such as the bones, lymph nodes, or distant organs. By inhibiting the growth of cancer cells and reducing the production of PSA, nilutamide may help slow down disease progression and improve survival outcomes in men with metastatic prostate cancer.

  4. Symptom Relief: In addition to its anticancer effects, nilutamide may also provide symptom relief in men with advanced prostate cancer. By reducing the size of the prostate tumor and alleviating pressure on surrounding tissues and organs, nilutamide can help alleviate symptoms such as urinary obstruction, bone pain, and other complications associated with advanced prostate cancer.

  5. Side Effects: Common side effects of nilutamide may include hot flashes, decreased libido, erectile dysfunction, breast tenderness or enlargement (gynecomastia), nausea, vomiting, diarrhea, fatigue, and liver function abnormalities. Serious adverse effects such as hepatotoxicity (liver damage), interstitial pneumonitis, and visual disturbances (including impaired dark adaptation and night blindness) are rare but may occur with prolonged use of nilutamide.

  6. Monitoring: Patients receiving nilutamide therapy require regular monitoring of liver function tests (LFTs), serum PSA levels, and ocular examinations to detect and manage any potential adverse effects or complications associated with treatment. Dosage adjustments or discontinuation of nilutamide may be necessary in cases of severe adverse reactions or hepatic dysfunction.

  7. Contraindications: Nilutamide is contraindicated in individuals with a history of hypersensitivity or allergic reactions to the medication, as well as in pregnant women or women of childbearing potential due to the risk of fetal harm. It should be used with caution in patients with preexisting liver disease or impairment.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of nilutamide,(prescription) On Probiotics

Rank Probiotic Impact
genus Bifidobacterium Reduces
species Bacteroides uniformis Reduces
species Bifidobacterium adolescentis Reduces
species Bifidobacterium longum Reduces
species Escherichia coli Reduces
species Parabacteroides distasonis Reduces
subspecies Bifidobacterium longum subsp. infantis Reduces
subspecies Bifidobacterium longum subsp. longum Reduces

Bacteria Impacted by nilutamide,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Mediterraneibacter genus Decreases 👪 Source Study
Collinsella genus Decreases 👪 Source Study proinflammatory
Blautia genus Decreases 👪 Source Study
Dorea genus Decreases 👪 Source Study
Lachnospira genus Decreases 👪 Source Study
Odoribacter genus Decreases 👪 Source Study
Phocaeicola genus Decreases 👪 Source Study
Veillonella genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Clostridioides genus Decreases 👪 Source Study
Escherichia genus Decreases 👪 Source Study
Ruminococcus genus Decreases 👪 Source Study
Clostridium genus Decreases 👪 Source Study Pathogen
Bacteroides genus Decreases 👪 Source Study
Agathobacter genus Decreases 👪 Source Study
Eggerthella genus Decreases 👪 Source Study
Fusobacterium genus Decreases 👪 Source Study Periodontal disease, Lemierre syndrome, skin ulcers
Bilophila genus Decreases 👪 Source Study High Level Cause Brain Fog(Cognitive impairment)
Thomasclavelia genus Decreases 👪 Source Study
Enterocloster genus Decreases 👪 Source Study
Bifidobacterium genus Decreases 👪 Source Study
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Coprococcus genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Lacrimispora genus Decreases 👪 Source Study
Escherichia coli O1:K1:H7 no rank Decreases 👶 Source Study
Escherichia coli O139:H1 no rank Decreases 👶 Source Study
Escherichia coli O141:H4 no rank Decreases 👶 Source Study
Escherichia coli O145:H34 no rank Decreases 👶 Source Study
Escherichia coli O15:H12 no rank Decreases 👶 Source Study
Escherichia coli O155:H21 no rank Decreases 👶 Source Study
Escherichia coli O158:H23 no rank Decreases 👶 Source Study
Escherichia coli O16:H48 no rank Decreases 👶 Source Study
Escherichia coli O170:H18 no rank Decreases 👶 Source Study
Escherichia coli O18ac:H14 no rank Decreases 👶 Source Study
Escherichia coli O19:H7 no rank Decreases 👶 Source Study
Escherichia coli O2:K1:H4 no rank Decreases 👶 Source Study
Escherichia coli O2:K1:H5 no rank Decreases 👶 Source Study
Escherichia coli O2:K1:H7 no rank Decreases 👶 Source Study
Escherichia coli O20:H12 no rank Decreases 👶 Source Study
Escherichia coli O25:H16 no rank Decreases 👶 Source Study
Escherichia coli O55:H7 no rank Decreases 👶 Source Study
Escherichia coli O68:H12 no rank Decreases 👶 Source Study
Escherichia coli O7:H15 no rank Decreases 👶 Source Study
Escherichia coli O78:H51 no rank Decreases 👶 Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
Escherichia coli O84:H7 no rank Decreases 👶 Source Study
Escherichia coli O85:H1 no rank Decreases 👶 Source Study
Clostridium perfringens A no rank Decreases 👶 Source Study
Clostridium perfringens B no rank Decreases 👶 Source Study
Clostridium perfringens D no rank Decreases 👶 Source Study
Clostridium perfringens E no rank Decreases 👶 Source Study
Escherichia coli O121 serogroup Decreases 👶 Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O155 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O177 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O3 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O78 serogroup Decreases 👶 Source Study
Escherichia coli O86 serogroup Decreases 👶 Source Study
Escherichia coli O91 serogroup Decreases 👶 Source Study
Escherichia coli H20 serotype Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O1:HNT serotype Decreases 👶 Source Study
Escherichia coli O10:H32 serotype Decreases 👶 Source Study
Escherichia coli O100:H21 serotype Decreases 👶 Source Study
Escherichia coli O103:H2 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O111:H- serotype Decreases 👶 Source Study
Escherichia coli O111:H8 serotype Decreases 👶 Source Study
Escherichia coli O111:NM serotype Decreases 👶 Source Study
Escherichia coli O112ab:H8 serotype Decreases 👶 Source Study
Escherichia coli O112ac:H19 serotype Decreases 👶 Source Study
Escherichia coli O113:H21 serotype Decreases 👶 Source Study
Escherichia coli O114:H49 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O125ac:K+:H10 serotype Decreases 👶 Source Study
Escherichia coli O126:H45 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O128ac:H12 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O145:H25 serotype Decreases 👶 Source Study
Escherichia coli O145:H28 serotype Decreases 👶 Source Study
Escherichia coli O145:NM serotype Decreases 👶 Source Study
Escherichia coli O15:H18 serotype Decreases 👶 Source Study
Escherichia coli O150:H6 serotype Decreases 👶 Source Study
Escherichia coli O152:H23 serotype Decreases 👶 Source Study
Escherichia coli O157:H- serotype Decreases 👶 Source Study
Escherichia coli O157:H43 serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O16:H6 serotype Decreases 👶 Source Study
Escherichia coli O167:H26 serotype Decreases 👶 Source Study
Escherichia coli O174:H21 serotype Decreases 👶 Source Study
Escherichia coli O176:H45 serotype Decreases 👶 Source Study
Escherichia coli O2:H6 serotype Decreases 👶 Source Study
Escherichia coli O2:K2:H1 serotype Decreases 👶 Source Study
Escherichia coli O25:H1 serotype Decreases 👶 Source Study
Escherichia coli O25:NM serotype Decreases 👶 Source Study
Escherichia coli O26:H11 serotype Decreases 👶 Source Study
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O45:H2 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O6:K2:H1 serotype Decreases 👶 Source Study
Escherichia coli O7:H4 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Escherichia coli O78:H4 serotype Decreases 👶 Source Study
Escherichia coli O8:H8 serotype Decreases 👶 Source Study
Escherichia coli O89m:H10 serotype Decreases 👶 Source Study
Escherichia coli O89m:H9 serotype Decreases 👶 Source Study
Escherichia coli O9:H10 serotype Decreases 👶 Source Study
Escherichia coli O99:H6 serotype Decreases 👶 Source Study
[Ruminococcus] torques species Decreases 📓 Source Study
Collinsella aerofaciens species Decreases 📓 Source Study
Blautia obeum species Decreases 📓 Source Study
Dorea formicigenerans species Decreases 📓 Source Study
Roseburia hominis species Decreases 📓 Source Study
Lachnospira eligens species Decreases 📓 Source Study
Bifidobacterium adolescentis species Decreases 📓 Source Study
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Odoribacter splanchnicus species Decreases 📓 Source Study
Phocaeicola vulgatus species Decreases 📓 Source Study
Bacteroides ovatus species Decreases 📓 Source Study
Veillonella parvula species Decreases 📓 Source Study
Bacteroides caccae species Decreases 📓 Source Study
Clostridioides difficile species Decreases 📓 Source Study Colitis
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Ruminococcus bromii species Decreases 📓 Source Study
Clostridium perfringens species Decreases 📓 Source Study Food poisoning, gas gangrene
Bacteroides thetaiotaomicron species Decreases 📓 Source Study
Agathobacter rectalis species Decreases 📓 Source Study
Eggerthella lenta species Decreases 📓 Source Study
Fusobacterium nucleatum species Decreases 📓 Source Study Infectious bacteria
Parabacteroides merdae species Decreases 📓 Source Study Infectious bacteria
Bilophila wadsworthia species Decreases 📓 Source Study
Thomasclavelia ramosa species Decreases 📓 Source Study
Enterocloster bolteae species Decreases 📓 Source Study
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Roseburia intestinalis species Decreases 📓 Source Study
Coprococcus comes species Decreases 📓 Source Study
Streptococcus parasanguinis species Decreases 📓 Source Study
Parabacteroides distasonis species Decreases 📓 Source Study
Bacteroides xylanisolvens species Decreases 📓 Source Study
Streptococcus salivarius species Decreases 📓 Source Study Infectious bacteria
Lacrimispora saccharolytica species Decreases 📓 Source Study
Bifidobacterium longum species Decreases 📓 Source Study
Fusobacterium nucleatum subsp. nucleatum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. infantis subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. longum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. suillum subspecies Decreases 👶 Source Study

Impact of nilutamide,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.3 0.3
Acne 0.2 -0.2
ADHD 4.6 0.5 8.2
Age-Related Macular Degeneration and Glaucoma 0.8 0.2 3
Allergic Rhinitis (Hay Fever) 1.1 1.2 -0.09
Allergies 5 1.8 1.78
Allergy to milk products 1.6 0.8 1
Alopecia (Hair Loss) 1.7 1.7
Alzheimer's disease 3.8 6.7 -0.76
Amyotrophic lateral sclerosis (ALS) Motor Neuron 2.9 1 1.9
Ankylosing spondylitis 3.5 1.3 1.69
Anorexia Nervosa 0.2 2.5 -11.5
Antiphospholipid syndrome (APS) 1.8 0.3 5
Asthma 1.1 0.6 0.83
Atherosclerosis 1.3 1.9 -0.46
Atrial fibrillation 3.4 1.3 1.62
Autism 8.4 8 0.05
Barrett esophagus cancer 0.6 0.2 2
benign prostatic hyperplasia 0.3 0.3
Biofilm 1.6 1.6
Bipolar Disorder 1.4 1.5 -0.07
Brain Trauma 0.7 0.6 0.17
Cancer (General) 0.4 2.3 -4.75
Carcinoma 3.9 2.9 0.34
Celiac Disease 2.6 3.5 -0.35
Cerebral Palsy 1.1 1.4 -0.27
Chronic Fatigue Syndrome 6.6 7.4 -0.12
Chronic Kidney Disease 2.1 2 0.05
Chronic Lyme 0.6 -0.6
Chronic Obstructive Pulmonary Disease (COPD) 1.4 1 0.4
Chronic Urticaria (Hives) 1.8 0.4 3.5
Coagulation / Micro clot triggering bacteria 1.3 1.3 0
Colorectal Cancer 4.3 1 3.3
Constipation 1.8 0.8 1.25
Coronary artery disease 1.1 1 0.1
COVID-19 11.8 13.9 -0.18
Crohn's Disease 7.7 6 0.28
cystic fibrosis 1 0.9 0.11
deep vein thrombosis 1 0.8 0.25
Depression 8.4 6.5 0.29
Dermatomyositis 0.2 0.2 0
Eczema 0.7 1.4 -1
Endometriosis 3 1.5 1
Eosinophilic Esophagitis 0.3 0.4 -0.33
Epilepsy 2.7 1.7 0.59
Fibromyalgia 2.8 2 0.4
Functional constipation / chronic idiopathic constipation 5.3 3.5 0.51
gallstone disease (gsd) 2.5 0.8 2.13
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 1.9 1.1 0.73
Generalized anxiety disorder 1.7 1.1 0.55
giant cell arteritis 0.3 -0.3
Glioblastoma 0.2 -0.2
Gout 0.2 -0.2
Graves' disease 1.2 1.8 -0.5
Halitosis 0.9 0.2 3.5
Hashimoto's thyroiditis 2.8 0.8 2.5
Hidradenitis Suppurativa 0.7 0.4 0.75
High Histamine/low DAO 1.9 0.6 2.17
hypercholesterolemia (High Cholesterol) 0.7 0.7
hyperglycemia 0.3 1.2 -3
Hyperlipidemia (High Blood Fats) 0.7 0.5 0.4
hypersomnia 0.7 -0.7
hypertension (High Blood Pressure 2 5.2 -1.6
Hypothyroidism 1.2 -1.2
Hypoxia 0.5 0.5
IgA nephropathy (IgAN) 3.6 -3.6
Inflammatory Bowel Disease 3.6 6.3 -0.75
Insomnia 0.9 1.1 -0.22
Intelligence 1.3 1.3
Intracranial aneurysms 1.3 0.5 1.6
Irritable Bowel Syndrome 4.1 4.3 -0.05
Liver Cirrhosis 4.6 2.9 0.59
Long COVID 7.6 9.6 -0.26
Low bone mineral density 1 -1
Lung Cancer 1.1 1.3 -0.18
Mast Cell Issues / mastitis 0.5 0.7 -0.4
ME/CFS with IBS 0.9 2.8 -2.11
ME/CFS without IBS 1.3 2.2 -0.69
Menopause 1.7 1.7
Metabolic Syndrome 7.8 7.8 0
Mood Disorders 11 6.8 0.62
multiple chemical sensitivity [MCS] 0.8 0.5 0.6
Multiple Sclerosis 3.8 4.4 -0.16
Multiple system atrophy (MSA) 1.3 1 0.3
neuropathic pain 1.7 -1.7
Neuropathy (all types) 0.6 0.3 1
neuropsychiatric disorders (PANDAS, PANS) 1.1 1.1
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 2.2 4.8 -1.18
NonCeliac Gluten Sensitivity 1.5 0.5 2
Obesity 9.4 3.6 1.61
obsessive-compulsive disorder 7.5 3.3 1.27
Osteoarthritis 1.6 0.3 4.33
Osteoporosis 1.9 0.8 1.37
pancreatic cancer 0.6 0.6
Parkinson's Disease 6 5.2 0.15
Polycystic ovary syndrome 2.7 1.9 0.42
Postural orthostatic tachycardia syndrome 0.3 0.4 -0.33
Premenstrual dysphoric disorder 1.2 0.2 5
primary biliary cholangitis 0.5 1.3 -1.6
Psoriasis 4.9 1.3 2.77
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 6 3.8 0.58
Rosacea 1.6 0.6 1.67
Schizophrenia 6.5 1.9 2.42
scoliosis 0.2 1.5 -6.5
Sjögren syndrome 2.7 3.6 -0.33
Sleep Apnea 1.5 1.6 -0.07
Slow gastric motility / Gastroparesis 1.7 0.2 7.5
Small Intestinal Bacterial Overgrowth (SIBO) 1.1 0.1 10
Stress / posttraumatic stress disorder 2.8 2.1 0.33
Systemic Lupus Erythematosus 3.7 2.2 0.68
Tic Disorder 1.5 1.2 0.25
Tourette syndrome 0.3 -0.3
Type 1 Diabetes 4.2 2.9 0.45
Type 2 Diabetes 8.3 6.5 0.28
Ulcerative colitis 2.9 4.6 -0.59
Unhealthy Ageing 5.7 1.7 2.35
Vitiligo 1.6 1.1 0.45

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.

Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions /Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [34.204.176 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [34.204.176 ]